EU/3/18/2001: Orphan designation for the prevention of ricin poisoning

Recombinant modified ricin toxin A-chain subunit


On 21 March 2018, orphan designation (EU/3/18/2001) was granted by the European Commission to Soligenix UK Ltd., United Kingdom, for recombinant modified ricin toxin A-chain subunit (also known as RiVax) for the prevention of ricin poisoning.

The sponsorship was transferred to Soligenix, the Netherlands, in June 2020.

Key facts

Active substance
Recombinant modified ricin toxin A-chain subunit
Intended use
Prevention of ricin poisoning
Orphan designation status
EU designation number
Date of designation

Soligenix NE B.V.
Joop Geesinkweg 901
1114 AB Amsterdam-Duivendrecht

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating